- Home
- RC vs CRVS Comparison
RC vs CRVS Comparison
Compare RC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- CRVS
- Stock Information
- Founded
- RC 2007
- CRVS 2014
- Country
- RC United States
- CRVS United States
- Employees
- RC N/A
- CRVS N/A
- Industry
- RC Real Estate Investment Trusts
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- CRVS Health Care
- Exchange
- RC Nasdaq
- CRVS Nasdaq
- Market Cap
- RC 517.6M
- CRVS 459.0M
- IPO Year
- RC N/A
- CRVS 2016
- Fundamental
- Price
- RC $3.05
- CRVS $7.68
- Analyst Decision
- RC Hold
- CRVS Strong Buy
- Analyst Count
- RC 5
- CRVS 4
- Target Price
- RC $6.10
- CRVS $13.75
- AVG Volume (30 Days)
- RC 2.3M
- CRVS 1.0M
- Earning Date
- RC 11-07-2025
- CRVS 11-04-2025
- Dividend Yield
- RC 16.39%
- CRVS N/A
- EPS Growth
- RC N/A
- CRVS N/A
- EPS
- RC N/A
- CRVS N/A
- Revenue
- RC N/A
- CRVS N/A
- Revenue This Year
- RC N/A
- CRVS N/A
- Revenue Next Year
- RC $141.93
- CRVS N/A
- P/E Ratio
- RC N/A
- CRVS N/A
- Revenue Growth
- RC N/A
- CRVS N/A
- 52 Week Low
- RC $3.02
- CRVS $2.54
- 52 Week High
- RC $7.64
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- RC 25.78
- CRVS 59.87
- Support Level
- RC $3.05
- CRVS $6.81
- Resistance Level
- RC $3.22
- CRVS $7.96
- Average True Range (ATR)
- RC 0.10
- CRVS 0.53
- MACD
- RC -0.00
- CRVS -0.02
- Stochastic Oscillator
- RC 6.00
- CRVS 75.00
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).